Guided Therapeutics (GTHP) insider reshapes stake via warrant exchange and preferred conversions
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Guided Therapeutics Inc. director and 10% owner Richard P. Blumberg reported a series of equity restructurings and conversions. He entered an exchange agreement in February 2026 under which 1,000,000 warrants with a $0.50 exercise price were exchanged for 1,000,000 warrants at $0.20 and immediately exercised for $200,000, delivering 1,000,000 shares of common stock.
In the same agreement, the expiration of 1,000,000 warrants with a $0.65 exercise price was extended to September 1, 2027, while 900,000 warrants at $0.30 issued in 2023 expired unexercised on March 1, 2026. On March 26, 2026, Blumberg converted 260 shares of Series F preferred stock into 1,040,000 common shares and 88 shares of Series F‑2 preferred into 352,000 common shares, and also received additional common shares as payment of accrued dividends at a conversion price of $0.2773 per share.
He was also granted 110,000 stock options with a $0.29 exercise price expiring in 2036, with vesting through March 10, 2029. One transaction line shows direct ownership of 10,391,311 common shares following these events.
Positive
- None.
Negative
- None.
Insider Trade Summary
1,000,000 shares exercised/converted
Mixed
14 txns
Insider
Blumberg Richard P.
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Warrants | 1,000,000 | $0.00 | -- |
| Grant/Award | Warrants | 1,000,000 | $0.00 | -- |
| Disposition | Warrants | 1,000,000 | $0.00 | -- |
| Grant/Award | Warrants | 1,000,000 | $0.00 | -- |
| Exercise | Warrants | 1,000,000 | $0.20 | $200K |
| H | Warrants | 900,000 | $0.30 | $270K |
| Grant/Award | Stock Options | 110,000 | $0.00 | -- |
| Exercise | Common Stock | 1,000,000 | $0.00 | -- |
| Other | Common Stock | 56,093 | $0.00 | -- |
| Other | Preferred Series F Stock | 260 | $0.00 | -- |
| Other | Common Stock | 1,040,000 | $0.00 | -- |
| Other | Common Stock | 19,038 | $0.00 | -- |
| Other | Preferred Series F-2 Stock | 88 | $0.00 | -- |
| Other | Common Stock | 352,000 | $0.00 | -- |
Holdings After Transaction:
Warrants — 0 shares (Direct, null);
Stock Options — 110,000 shares (Direct, null);
Common Stock — 8,924,180 shares (Direct, null);
Preferred Series F Stock — 0 shares (Direct, null);
Preferred Series F-2 Stock — 0 shares (Direct, null)
Footnotes (1)
- During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027. 900,000 warrants to purchase shares of common stock with an exercise price of $0.30, with an issuance date of March 1, 2023, expired on March 1, 2026, without being exercised. One-fourth of the shares subject to the award vested on March 10, 2026; the remaining shares will vest monthly, starting on June 10, 2026, subject to the reporting person's continued service on each such date, until the award is fully vested on March 10, 2029. These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.2773. On March 26, 2026, Mr. Blumberg converted 260 shares of Series F preferred stock into 1,040,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price. These shares were issued for payment of accrued dividends on the reporting individual's Series F-2 preferred stock, at a conversion price of $0.2773. On March 26, 2026, Mr. Blumberg converted 88 shares of Series F-2 preferred stock into 352,000 shares of common stock. The Series F-2 preferred stock had a stated value of $1,000 and $0.25 conversion price.
Key Figures
Warrants exchanged and exercised: 1,000,000 warrants at $0.20
Cash paid on warrant exercise: $200,000
Series F conversion: 1,040,000 common shares
+5 more
8 metrics
Warrants exchanged and exercised
1,000,000 warrants at $0.20
Exchanged from $0.50 warrants and immediately exercised for $200,000
Cash paid on warrant exercise
$200,000
Payment to exercise 1,000,000 newly issued $0.20 warrants
Series F conversion
1,040,000 common shares
Conversion of 260 Series F preferred at $0.25 conversion price
Series F-2 conversion
352,000 common shares
Conversion of 88 Series F-2 preferred at $0.25 conversion price
Expired warrants
900,000 warrants at $0.30
Issued March 1, 2023; expired unexercised on March 1, 2026
Stock option grant
110,000 options at $0.29
Expires in 2036, fully vests by March 10, 2029
Common shares after events
10,391,311 shares
Direct common stock ownership shown after one reported transaction line
Dividend conversion price
$0.2773 per share
Price used to issue common shares for accrued preferred dividends
Key Terms
exchange agreement, Series F preferred stock, Series F-2 preferred stock, warrants, +2 more
6 terms
exchange agreement financial
"entered into an exchange agreement pursuant to which 1,000,000 warrants"
Series F preferred stock financial
"converted 260 shares of Series F preferred stock into 1,040,000 shares"
Series F preferred stock is a class of company shares that gives holders priority over common shareholders for dividend payments and for getting money back if the company is sold or liquidated, much like a ticket that moves you to the front of the line. These shares often carry a fixed dividend and special rights—sometimes including conversion into common stock—so investors consider them when weighing income, downside protection and potential ownership dilution.
Series F-2 preferred stock financial
"converted 88 shares of Series F-2 preferred stock into 352,000 shares"
warrants financial
"1,000,000 warrants to purchase shares of common stock with an exercise price"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
stock options financial
"One-fourth of the shares subject to the award vested on March 10, 2026"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
conversion price financial
"accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.2773"
The conversion price is the fixed price at which a convertible security, like a bond or preferred stock, can be exchanged for shares of common stock. It acts like a set rate that determines how many shares an investor can receive if they choose to convert their investment. This helps investors understand the value and potential benefits of converting their securities into company shares.
FAQ
What insider transactions did Richard P. Blumberg report at GUIDED THERAPEUTICS INC (GTHP)?
He reported warrant exchanges and exercises, preferred stock conversions into common shares, warrant expirations, and a new stock option grant. These actions reshape his equity mix between common stock, warrants, and options without any open-market share purchases or sales disclosed.
How many GUIDED THERAPEUTICS (GTHP) warrants did Blumberg exchange and exercise?
He exchanged 1,000,000 warrants with a $0.50 exercise price for 1,000,000 warrants at $0.20, then immediately exercised them for $200,000. This exercise resulted in 1,000,000 new common shares being issued under the revised, lower exercise price.
Did any GUIDED THERAPEUTICS (GTHP) warrants held by Blumberg expire unused?
Yes. Footnotes state that 900,000 warrants with a $0.30 exercise price, issued March 1, 2023, expired on March 1, 2026 without being exercised. This eliminated those potential future common shares tied to that specific warrant series.
What new stock options did Blumberg receive from GUIDED THERAPEUTICS (GTHP)?
He was granted 110,000 stock options with a $0.29 exercise price, expiring in 2036. One-fourth vested on March 10, 2026, and the remainder will vest monthly from June 10, 2026, until full vesting on March 10, 2029, subject to continued service.